ClinicalTrials.gg
RecruitingNCT06923644PRECINUTUpdated Jan 20, 2026

Targeted Precision Nutrition Strategy To Prevent Chronic Metabolic Diseases

An interventional study of Optimal Metabotype-specific diet and Sub-optimal diet in Obesity and Overweight, Pre-diabetic and Type 2 Diabetes Mellitus (T2DM), sponsored by Maastricht University Medical Center. Recruiting at 2 sites in Netherlands. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Obesity by Maastricht University Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Obesity · Maastricht University Medical Center.

Planned enrollment
2nd of 67
240 · median 40
Started
2025
with 1 other
No phase
65 of 75
4 open now
Registered
72nd of 75
by date

Among the 75 studies in Obesity by Maastricht University Medical Center, this one is the 2nd largest by planned enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2025, is one of 65 with no phase, and was the 72nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 75 studies in Obesity by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Obesity by Maastricht University Medical Center, or all of them as a file.
02

Study summary

Nutrition is very important to keep blood sugar levels balanced. If blood sugar levels are too high, it can lead to diseases such as cardiovascular disease and type 2 diabetes (T2DM). Therefore, adjusting what one eats, also called a diet or nutritional intervention, can help prevent these diseases. However, not everyone responds the same to a diet. In about 30% of people, a diet does not work as hoped. This can be due to various reasons, such as a person's metabolism, genetic predisposition, the composition of the food one eats, or the bacteria in the intestines. Everyday things like sleep, stress, and movement also play a role. The investigators used a computer model to classify people with overweight and obesity into groups based on these factors. The investigators call such a group a 'Metabolic Phenotype', or in short 'Metabotype'. Based on the Metabotype, a personalised diet was developed (personalised nutrition intervention) that may better suit each person's unique situation.

The investigators hypothesize that a precision nutrition intervention, tailored to Metabotypes identified through unsupervised clustering (using the aforementioned computer model) of predefined, accurate features related to cardiometabolic health-specifically, tissue-specific glucose and lipid metabolism and detailed body composition-will enhance blood glucose homeostasis, reduce cardiometabolic risk, and improve adherence to the intervention and mental well-being, compared to population-based dietary guidelines. The present project will contribute to targeted and efficient precision-based dietary strategies for individuals at increased risk of T2DM.

Read the detailed description

Objective:

Our study aims to identify unique Metabotypes among individuals with overweight and obesity and assess their response to a 1-year precision dietary macronutrient modulation. The objective is to provide proof-of-concept that this approach improves glucose homeostasis, dietary adherence, and psychosocial well-being compared to population-based dietary guidelines.

Study design:

Two-centre dietary intervention study with a double-blind, randomised controlled parallel design, based on participants' Metabotype and hypothesized optimal diet. Participants' Metabotype and intervention arm will be blinded to the participants and researchers. Metabotypes were identified through hierarchical clustering of Principal Components (HCPC) using baseline data from The Maastricht Study (participant demographics, body composition, glucose- and insulin metabolism), whereafter clusters were cross-validated in independent cohorts. Based on a combination of post-hoc analyses of dietary intervention trials and literature, the optimal dietary macronutrient composition was determined for these Metabotypes.

Study population:

In total 240 men and women with overweight and obesity (age 40-75 years, BMI 25-40 kg/m2) will be included. Further details on in- and exclusion criteria will be described under ''Eligibility''. Following screening and baseline measurements, for each eligible participant, a classification algorithm will determine the participants' Metabotype cluster (one of three possible Metabotypes for each sex).

Intervention:

Following screening, baseline measurements, and determination of Metabotype, participants will be randomly assigned, using minimization, to either the Precision Nutrition (PN) group or the Control (CN) group. The PN group will receive a hypothesized optimal diet for their specific Metabotype, while the control group will be randomly assigned one of the diets optimized for a different Metabotype of the same sex. All participants will follow their assigned diets for 12 months, with each diet conforming to the Dutch healthy dietary guidelines. Participants will receive regular dietary consultation, and meal plans including variation lists to guide them with their dietary intake during the intervention.

Main study parameters/endpoints:

Extensive characterization will be done before, during, and after the intervention. Primary outcome measure is whole-body insulin sensitivity (Matsuda index) assessed by means of a 7-point oral glucose tolerance test (OGTT). Secondary outcomes include glycaemic variability, mean glucose levels, fasting lipid profiles, body composition, blood pressure, gene and protein expression of adipose tissue, microbial composition and functionality, metabolomics, physical activity, adherence to dietary recommendations, (mental) well-being, and quality of life.

03

Conditions studied

  • Obesity and Overweight
  • Pre-diabetic
  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Dietary intervention trial
  • Precision nutrition
  • Tissue-specific insulin resistance
  • Body composition
  • Metabotyping
  • Glucose homeostasis
  • Cardiometabolic health
  • Insulin resistance
  • Metabolic phenotype
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women with a ≥25 to \<40 kg/m2
  • Classification possible to one of the metabolic phenotypes according to the classification algorithm.
  • Weight stability for at least 3 months (+/- 3 kg)

Exclusion criteria

Exclusion Criteria:

Diseases

  • (Pre-)diagnosis of type 1 or type 2 diabetes mellitus (i.e., FPG ≥ 7,0 mmol/L) and ≥ 6,5% (48 mmol/mol)
  • Renal or hepatic malfunctioning (pre-diagnosis or determined based on ALAT and creatinine values)
  • Gastrointestinal diseases or abdominal surgery (allowed i.e.:

appendectomy, cholecystectomy)

  • Food allergies, intolerances (including gluten/lactose intolerance) and/or eating disorders interfering with the study
  • Cardiovascular diseases (e.g., heart failure) or cancer (e.g., noninvasive skin cancer allowed)
  • High systolic blood pressure (untreated >160/100 mmHg, drug-regulated >140/90 mmHg)
  • Diseases affecting glucose and/or lipid metabolism (e.g., pheochromocytoma, Cushing's syndrome, acromegaly)
  • Diseases with a life expectation shorter than 5 years
  • Major mental disorders
  • Drug treated thyroid diseases (well substituted hypothyroidism is allowed inclusion)
  • Other physical/mental conditions that may interfere with study outcomes

Medication

  • Medication known to interfere with study outcomes (e.g., PPAR-α or PPAR-γ agonists (fibrates), sulfonylureas, biguanides, α-glucosidaseinhibitors, thiazolidinediones, repaglinide, nateglinide, insulin, and chronic use of NSAIDs)
  • Use of certain anticoagulants other than acetylsalicylic acid
  • Use of antidepressants (stable use ≥ 3 months prior to and during study allowed)
  • Use of statins (stable use ≥ 3 months prior to and during study allowed)
  • Chronic treatment (>7 consecutive days of treatment)
  • Use of antibiotics within 3 months prior to the study

Lifestyle

  • Participation in regular sports activities (moderate-to-vigorous physical exercise >4 hours per week)
  • Having a restricted dietary pattern interfering with the study diets (e.g., vegetarian, vegan, Atkins diet and/or other special diets)
  • Plans to lose or gain more than 5% body weight
  • Abuse of alcohol (alcohol consumption >14 units/week) and/or drugs (cannabis included)
  • Not willing to limit alcohol consumption to 7 drinks per week
  • Regular smoking (including use of e-cigarettes and vapes)
  • Use of strong vitamins or other dietary supplements (e.g., pre- or probiotics) expected to interfere with the study outcomes

Other

  • Metabotype classification is not possible
  • Pregnant or lactating women, or women who are planning to become pregnant
  • Inability to comply with the study diet
  • Blood donation within the last 3 months
  • Participation in possibly interfering studies within the last 3 months
  • Inability to understand study information and/or communicate with staff
  • Unwillingness to be randomised or sign
  • Unwillingness to save data for 15 years
  • Deemed unsuitable for participation in the trial, for any reason, as judged by the research physician or principal investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Precision Nutrition Group (PN)

    For a total duration of 12 months, participants in the Precision Nutrition (PN) Group will follow a diet tailored to their Metabotype, which is hypothesised to be optimal for them.

    Other: Optimal Metabotype-specific diet

  • Experimental
    Control Group (CN)

    For a total duration of 12 months, participants in the Control Group (CN) will be randomly assigned one of the diets optimised for a different Metabotype of the same sex, which is hypothesised to be suboptimal for them.

    Other: Sub-optimal diet

Interventions

  • OtherOptimal Metabotype-specific diet

    Following screening, baseline measurements, and determination of Metabotype, participants will be randomly assigned, using minimisation, to either the Precision Nutrition (PN) group or the Control (CN) group. The PN group will receive a diet hypothesised to be optimal for their specific Metabotype. All participants will adhere to their assigned diets for 12 months. Each Metabotype-specific diet will align with the Dutch Healthy Dietary Guidelines, while varying in macronutrient composition and quality.

  • OtherSub-optimal diet

    Participants randomised to the Control Group (CN), will be randomly assigned one of the two diets optimised for a different Metabotype of the same sex. The assigned CN Group diet will always have a macronutrient content and quality that is different than their hypothesised optimal diet. All diets will align with the Dutch Healthy Dietary Guidelines.

06

What researchers measure

Primary outcomes

  1. Matsuda Index

    The primary objective of this study is to evaluate the effect of a 12-month Metabotype-targeted diet (PN) versus a non-targeted diet (CN) on whole-body insulin sensitivity (Matsuda Index; marker of whole-body fasting and postprandial insulin sensitivity). This will include within group post-hoc testing. The primary outcome measure will be assessed by means of a 7-point oral glucose tolerance test (OGTT), and calculated as follows: \[10,000 / square root of \[fasting plasma glucose (mg/dL) × fasting insulin (mU/L)\] × \[mean glucose (mg/dL) x mean insulin (mU/L)\]\].

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

Secondary outcomes

  1. Glucose tolerance

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Determined by 2-hour plasma glucose values (mmol/L) during an oral glucose tolerance test (OGTT).

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  2. Disposition Index (DI)

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. The Disposition Index is a composite marker of first phase insulin secretion and insulin sensitivity during a 2-hour 7-point oral glucose tolerance test (OGTT). Disposition index will be calculated as follows: \[Insulin sensitivity index (ISI) \* (AUC30 min insulin / AUC30 min glucose)\], where AUC30 min is the area under the curve between 0 and 30 minutes of the OGTT for insulin (pmol/l) and glucose (mmol/l), respectively, and ISI is defined as: \[10,000 ÷ square root of (fasting plasma glucose (mmol/l) x fasting insulin (pmol/l)) x (mean glucose (mmol/l) x mean insulin (pmol/l))\]. Higher values represent a higher insulin sensitivity.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  3. HOMA-IR

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. HOMA-IR is a fasting measure for insulin resistance, which can be calculated as follows: HOMA-IR = (Fasting plasma glucose (mmol/L) \* Fasting Insulin (mU/L)) / 22.5. Higher values represent a higher degree of insulin resistance. Determined in plasma during a 2-hour, 7-points oral glucose tolerance test (OGTT).

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  4. Muscle insulin sensitivity (MISI)

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Determined during a 2-hour, 7-point oral glucose tolerance test (OGTT). The muscle insulin sensitivity index (MISI) will be calculated as follows: MISI (mmol/l/min/pmol/l) = (dG/dt) / mean plasma insulin concentration (pmol/l) during OGTT. Here, dG/dt is the rate of decay of plasma glucose concentration (mmol/L) during the OGTT, calculated as the slope of the least square fit to the decline in plasma glucose concentration from peak to nadir. Higher values represent higher muscle insulin sensitivity.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  5. Hepatic insulin resistance (HIRI)

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Determined during a 2-hour, 7-point oral glucose tolerance test (OGTT). The hepatic insulin resistance index (HIRI) will be calculated using the square root of the product of the area under curves (AUCs) for plasma glucose and insulin during the first 30 min of the OGTT - i.e., square root (glucose0-30 \[AUC in mmol/l·h\] · insulin 0-30 \[AUC in pmol/l·h). Higher HIRI values represent lower hepatic insulin sensitivity.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  6. Adipose tissue insulin sensitivity (ATIRI)

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. The Adipose Tissue Insulin Resistance Index (ATIRI) is an indicator of the degree of insulin resistance in adipose tissue. Determined during a 2-hour, 7-point oral glucose tolerance test (OGTT), using fasting plasma insulin and free fatty acids (FFA) concentrations. ATIRI is calculated as: fasting FFA (mmol/L) \* fasting Insulin (pmol/L. Higher ATIRI values represent lower adipose tissue insulin sensitivity.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  7. Insulinogenic Index (IGI)

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Determined during a 2-hour, 7-point oral glucose tolerance test (OGTT). The Insulinogenic Index (IGI) is a measure used to assess the early insulin response of the pancreas to a glucose load. IGI is calculated as: Plasma Insulin 0 - 30 \[AUC in pmol/L x min\] / Glucose 0 - 30 \[AUC in mmol/L x min\]. Higher IGI values represent a higher proportional secretion of insulin in response to insulin, indicative of a proportional increased pancreatic secretion of insulin.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  8. HOMA-β

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Determined during a 2-hour, 7-point oral glucose tolerance test (OGTT), based on fasting plasma glucose and fasting insulin levels. Homeostatic Model Assessment of Beta-cell function (HOMA-β) is a mathematical model used to estimate the function of pancreatic beta-cells, which are responsible for producing insulin. HOMA-β is calculated as: 20 × (fasting insulin (mU/L) / (fasting glucose (mmol/L) - 3.5). Normal values are \~100, higher values are indicative of increased Beta-cell activity, while lower values are indicative of decreased Beta-cell activity.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  9. Circulating hormones such as Insulin

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Circulating hormones such as insulin are determined in plasma during a 2-hour, 7-point oral glucose tolerance test (OGTT).

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  10. Body composition

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Body composition such as the Android/Gynoid fat mass ratio (unitless) will be determined by using a dual-energy X-ray absorptiometry scan (DXA).

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  11. Waist circumference

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Waist circumference in centimeters.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  12. Hip circumference

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Hip circumference in centimeters.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  13. Waist-to-hip ratio (WHR)

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Waist circumference in centimeters, divided by the hip circumference in centimeters, expressed as a unitless ratio.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  14. Subcutaneous adipose tissue gene expression

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Subcutaneous adipose tissue biopsies will be taken for gene expression analysis. Biopsies will only be obtained in a sub-group of participants at the MUMC+, none will be obtained from participants at WUR.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  15. Subcutaneous adipose tissue protein expression

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Subcutaneous adipose tissue biopsies will be taken for protein expression analysis. Biopsies will only be obtained in a sub-group of participants at the MUMC+, none will be obtained from participants at WUR.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  16. Blood pressure

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Systolic and diastolic blood pressure in mmHg.

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  17. Mean 24h glucose concentrations

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. For a 14-day period at the beginning and end of the intervention, mean 24-hour glucose levels will be monitored in all participants with a glucose sensor (FreeStyle libre 2, Research CGM, Abbot).

    Time frame: Change from baseline at month 12 following dietary intervention.

  18. Glucose incremental area under the curve (iAUC)

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. For a 14-day period at the beginning and end of the intervention, 24-hour glucose levels will be monitored in all participants with a glucose sensor (FreeStyle libre 2, Research CGM, Abbot). The net incremental area under the curve (iAUC) will be calculated by the trapezoid rule, using fasting glucose value as baseline. The iAUC provides a summary measure of the net increase in glucose levels above the fasting level during the 24-hour period.

    Time frame: Change from baseline at month 12 following dietary intervention.

  19. The frequency of hypo- and hyperglycemia

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. For a 14-day period at the beginning and end of the intervention, 24-hour glucose levels will be monitored in all participants with a glucose sensor (FreeStyle libre 2, Research CGM, Abbot). The frequency of hypo- and hyperglycaemia will be monitored and defined as occurrences of a glucose level of ≥10.0 mmol/l for hyperglycaemia, whilst hypoglycaemia will be defined as a glucose concentration ≤ 3.9 mmol/l.

    Time frame: Change from baseline at month 12 following dietary intervention.

  20. Mean Amplitude of Glucose Excursions (MAGE)

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. For a 14-day period at the beginning and end of the intervention, 24-hour glucose levels will be monitored in all participants with a glucose sensor (FreeStyle Libre 2, Research CGM, Abbott). The Mean Amplitude of Glucose Excursions (MAGE) will be calculated as the average of significant glucose fluctuations (excursions) above or below the mean glucose level. MAGE quantifies glycemic variability and is expressed in mmol/L.

    Time frame: Change from baseline at month 12 following dietary intervention.

  21. Time in Range (TIR)

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. For a 14-day period at the beginning and end of the intervention, 24-hour glucose levels will be monitored in all participants with a glucose sensor (FreeStyle Libre 2, Research CGM, Abbott). The Time in Range (TIR) will be defined as the percentage of time spent within the target glucose range of 3.9-10.0 mmol/L. Time spent below 3.9 mmol/L (time below range, TBR) and above 10.0 mmol/L (time above range, TAR) will also be calculated as secondary metrics.

    Time frame: Change from baseline at month 12 following dietary intervention.

  22. Coefficient of Variation (CV%)

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. For a 14-day period at the beginning and end of the intervention, 24-hour glucose levels will be monitored in all participants with a glucose sensor (FreeStyle Libre 2, Research CGM, Abbott). The Coefficient of Variation (CV%) will be calculated as the standard deviation of glucose divided by the mean glucose level, multiplied by 100. CV% expresses glucose variability as a percentage and reflects overall glycemic stability, with a CV% \> 36% considered indicative of high variability.

    Time frame: Change from baseline at month 12 following dietary intervention.

  23. Standard Deviation (SD) of Glucose Levels

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. For a 14-day period at the beginning and end of the intervention, 24-hour glucose levels will be monitored in all participants with a glucose sensor (FreeStyle Libre 2, Research CGM, Abbott). The Standard Deviation (SD) of glucose levels will be calculated as a measure of glycemic variability around the mean glucose concentration. A higher SD indicates greater glucose fluctuation and variability throughout the monitoring period.

    Time frame: Time Frame: Change from baseline at month 12 following dietary intervention.

  24. The duration of hypo- and hyperglycemia

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. For a 14-day period at the beginning and end of the intervention, 24-hour glucose levels will be monitored in all participants with a glucose sensor (FreeStyle libre 2, Research CGM, Abbot). The duration of hypo- and hyperglycaemia will be monitored and defined as time spent with a glucose level of ≥10.0 mmol/l for hyperglycaemia, whilst hypoglycaemia will be defined as a glucose concentration ≤ 3.9 mmol/l.

    Time frame: Change from baseline at month 12 following dietary intervention.

  25. Gut microbial composition

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Faecal samples to be used for analysing microbiota composition will be collected.

    Time frame: Change from baseline at month 12 following dietary intervention.

  26. Circulating SCFA

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Circulating Short Chain Fatty Acids (SCFAs) are determined in plasma during a 2-hour, 7-point oral glucose tolerance test (OGTT).

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  27. Targeted plasma metabolomics

    At baseline, a fasting blood sample will be collected during the oral glucose tolerance test (OGTT) for determination of the Metabotypes' metabolomics profile (Nightingale).

    Time frame: Baseline

  28. Circulating lipids such as FFA

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Circulating lipids such as Free Fatty Acids (FFA) are determined in serum during a 2-hour, 7-point oral glucose tolerance test (OGTT).

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  29. Circulating inflammatory markers such as CRP

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Circulating inflammatory markers such as C-Reactive Protein (CRP) are determined in plasma during a 2-hour, 7-point oral glucose tolerance test (OGTT).

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  30. Circulating HbA1c

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Circulating Hemoglobin A1c (HbA1c) is determined in plasma during a 2-hour, 7-point oral glucose tolerance test (OGTT).

    Time frame: Change from baseline at month 6 and month 12 following dietary intervention.

  31. Physical activity

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Physical activity patterns will be monitored continuously with the ActivPAL device during a 14-day period at baseline and at the end of the intervention.

    Time frame: Change from baseline at month 12 following dietary intervention.

  32. Self-reported self-efficacy

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Self-efficacy with regard to health behaviour is measured by the 13-item PAM-13 (Patient Activation Measurement questionnaire). Score ranges from 0-100, higher scores indicate a greater self-efficacy.

    Time frame: Change from baseline at month 6 and 12 following dietary intervention.

  33. Self-reported context-sensitive positive health

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Positive health is measured by the 23-item Context-sensitive Positive Health Questionnaire (CPHQ), which is a newly developed questionnaire still in the validation phase. Score ranges from 0-100, higher scores indicate a greater positive health.

    Time frame: Change from baseline at month 1 and 12 following dietary intervention.

  34. Self-reported mood

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Potential positive impacts on mood by the intervention are measured by the 20-item PANAS, resulting in a positive mood score (10-50; higher scores representing higher levels of positive mood), and negative mood score (10-50; lower scores representing lower levels of negative mood).

    Time frame: Change from baseline at month 6 and 12 following dietary intervention.

  35. Self-reported stool consistency

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Stool consistency is measured by the Bristol Stool Chart (BSC). Score ranges from 1-7, wherein 1-2 indicates constipation, 3-4 normal stool, and 5-7 diarrhoea.

    Time frame: Change from baseline at month 1 and 12 following dietary intervention.

  36. Self-reported fatigue

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Physical and mental fatigue are assessed using the 14-item Chalder fatigue scale. Scores range 0-42, wherein higher scores indicate increasing fatigue severity.

    Time frame: Change from baseline at month 12 following dietary intervention.

  37. Self-reported health-related quality of life

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Health-related quality of life is measured by the 6-item EQ5-D is a short scoring tool for mobility, self-care, daily activities, pain/discomfort and fear/depression, complementary to the CPHQ. The score consists of a health index (ranging from -0.59 to 1.00, with 1 being perfect health) based on aforementioned five dimensions and a visual analog scale (VAS) from 0 to 100 to assess self-rated health.

    Time frame: Change from baseline at month 1 and 12 following dietary intervention.

  38. Self-reported positive health

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Positive health is measured by the 17-item IPH-17, which is a shortened positive health questionnaire, complementary to the CPHQ. Scores range from 17-85, higher scores indicate more concerns about own health.

    Time frame: Change from baseline at month 1 and 12 following dietary intervention.

  39. Adherence to dietary recommendations

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. During the 12-month intervention period, dietary compliance will be assessed before each planned visit at 1, 3, 6, 9 and 12 months. In short, roughly two weeks before each visit, participants will receive a prompt to record their food intake on two week-days and one weekend-day via Traqq App. These recording days will be automised, unannounced and non-consecutive.

    Time frame: 12-months, continuously throughout the study

  40. Self-reported mental health

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Mental wellbeing is assessed using the RAND-36. Scored from 0 to 100, higher scores represent better mental health.

    Time frame: Change from baseline at month 6 and 12 following dietary intervention.

  41. Self-reported perceived stress

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Perceived stress is measured with the 10-item Perceived Stress Scale (PSS10). Scores range from 0-40, higher scores represent higher levels of perceived stress.

    Time frame: Change from baseline at month 6 and 12 following dietary intervention.

  42. Self-reported gastrointestinal health

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Gastrointestinal symptoms are assessed by the 15-item Gastrointestinal Symptom Rating Scale (GSRS). Scores range from 15-105, wherein higher scores indicate more severe discomfort.

    Time frame: Change from baseline at month 1 and 12 following dietary intervention.

  43. Self-reported sleep quality

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Sleep quality is assessed with the 10-item Pittsburgh Sleep Quality Index. Scores range 0-21, higher scores indicate worse sleep quality.

    Time frame: Change from baseline at month 12 following dietary intervention.

  44. Self-reported daytime sleepiness

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. Daytime sleepiness is assessed with the 8- item Epworth Sleepiness scale. Scores range 0-24, higher scores indicate greater daytime sleepiness.

    Time frame: Change from baseline at month 12 following dietary intervention.

  45. Self-reported chronotype

    Optimal (PN) versus sub-optimal (CN) diet, including within group post-hoc testing. The Munich Chronotype Questionnaire (MCTQ) assesses an individual's chronotype (biological sleep-wake preference) based on actual sleep behaviour on workdays and free days. MCTQ determines chronotype based on the midpoint of sleep on free days (MSF; hh:mm, 24-hour format)), adjusted for sleep debt (MSFsc; hh:mm, 24-hour format), and social jetlag (SJL; hh:mm, 24-hour format), where later MSFsc indicates an evening type and higher SJL reflects circadian misalignment.

    Time frame: Change from baseline at month 12 following dietary intervention.

  46. DNA analysis

    Buffy coats will be collected for DNA analysis, pre-intervention only, exploratory objective.

    Time frame: Baseline

Other outcomes

  1. Baseline characteristics

    Baseline characteristics (age, sex, ethnicity, lifestyle, socioeconomic status, medical history, medication use, family composition and history of T2DM, and menopausal state) will also be recorded, for the purpose of screening, metabolic classification and potential post-hoc analysis.

    Time frame: Baseline

  2. Metabotype cluster

    The Metabotype cluster (one of three possible groups for each sex) will be assessed at three time points. Namely, baseline, at 6 months and at 12 months. To determine the Metabotype, several outcome measures derived from the OGTT and anthropometrics will be aggregated by the described classification algorithm (see study description).

    Time frame: Baseline, and change from baseline at month 6 and month 12 following dietary intervention.

  3. Capillary Blood Samples (CBS)

    Capillary Blood Samples (CBS) samples will be obtained via fingerpick parallel to the venous fasting blood sample collected during the oral glucose tolerance test (OGTT). These samples will be analyzed to explore the feasibility of developing a simplified classification algorithm for determining Metabotype, providing a potentially more accessible and less invasive diagnostic approach. CBS will only be obtained in a sub-group of participants at the MUMC+, none will be obtained from participants at WUR.

    Time frame: Baseline and following 12 month dietary intervention.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Once the corresponding article is published and/or the project is finished, (part of) our metadata will be accessible for further research and verification. Interested researchers can submit a data request by means of a synopsis, this is necessary to prevent inappropriate use of data. A designated committee consisting of the project leader and the steering committee will decide on the approval of future requests (synopsis) for data access. At a minimum, the synopsis must show that the applicant's intended purpose and method of operation comply with the PRECINUT Data Terms of Use (see also access criteria), which have yet to be determined by the steering committee. Study participants will be provided with a participant number, which can only be connected to personal data via the informed consent form. The informed consent forms are only stored at the respective research sites separately (MUMC+/WUR), and will not be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Possibly, based on guidelines in the consortium agreement, the steering committee could agree on an embargo period, which could delay the accessibility of (part of) the data. One of the reasons for delayed data access may be the application for IP rights and marketing of the acquired knowledge (by consortium partners).

Access criteria: The purpose of data access is limited to scientific purposes and may not be used for commercial purposes; The purpose of the data request must be of public interest. Research questions of the data access applicant must be related to the research topic of the original study; The dataset must not be linked to an external dataset (for privacy reasons); Use of the dataset is not infinite, but only for a predetermined period, a time interval required for analyses of data up to a maximum of 3 months (and once for this specific question by this applicant); A small fee is requested for (re)use of the data. This fee will cover the additional costs associated with assessing the request and distributing the data; If the purpose of data access is scientific publication, agreements must be made in advance on co-authorship, access to the final manuscript and the possibility of stopping the publication of data up to a period of 3 months if no agreement can be reached between parties.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 24 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Apr 11, 2025
StartActual
Apr 23, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06923644
Collaborators
Wageningen University and Research, Health Holland, TKI Agri & Food, Nestle Health Science, Beneo GmbH, BARILLA G. e R. Fratelli S.p.A., Parma, Italy
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Apr 23, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jan 20, 2026

Study contacts

Ellen E Blaak, Prof. Dr. Ir.
Contact
e.blaak@maastrichtuniversity.nl
+31433881503
Art Muijsenberg, MSc
Contact
art.muijsenberg@maastrichtuniversity.nl
+31433882862
Ellen E Blaak, Prof. Dr. Ir.
principal investigator · Maastricht University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion